

# Michael G Schlossmacher

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2583272/publications.pdf>

Version: 2024-02-01

82  
papers

13,289  
citations

44444

50  
h-index

73587

79  
g-index

91  
all docs

91  
docs citations

91  
times ranked

13691  
citing authors

#	ARTICLE	IF	CITATIONS
1	BATL: Bayesian annotations for targeted lipidomics. <i>Bioinformatics</i> , 2022, 38, 1593-1599.	1.8	3
2	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. <i>Acta Neuropathologica</i> , 2021, 141, 725-754.	3.9	32
3	Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on the pathogenesis of Parkinson's disease. <i>Archives of Biochemistry and Biophysics</i> , 2021, 704, 108869.	1.4	16
4	Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 65.	2.5	74
5	Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome. <i>Microbes and Infection</i> , 2020, 22, 40-45.	1.0	7
6	Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?. <i>Movement Disorders</i> , 2020, 35, 1922-1932.	2.2	0
7	A $\beta$ oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner. <i>Science Signaling</i> , 2020, 13, .	1.6	45
8	Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S LRRK2 knock-in mice. <i>Brain, Behavior, &amp; Immunity - Health</i> , 2020, 5, 100079.	1.3	9
9	Performance report for a 10-year-old MD/PhD Program: A survey of trainees at the University of Ottawa. <i>Clinical and Investigative Medicine</i> , 2020, 43, E1-13.	0.3	2
10	Canadian guideline for Parkinson disease. <i>Cmaj</i> , 2019, 191, E989-E1004.	0.9	90
11	<i>lrrk2</i> alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	67
12	DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebroside in plasma and cerebrospinal fluid. <i>Journal of Lipid Research</i> , 2019, 60, 200-211.	2.0	15
13	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , 2018, 90, 74-82.	1.5	23
14	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5164-E5173.	3.3	83
15	Holocranohistochemistry enables the visualization of $\alpha$ -synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. <i>Journal of Neural Transmission</i> , 2017, 124, 721-738.	1.4	42
16	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	4.9	131
17	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the R-EDIGT score. <i>European Journal of Neuroscience</i> , 2017, 45, 175-191.	1.2	17
18	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2017, 14, 164.	3.1	64

#	ARTICLE	IF	CITATIONS
19	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
20	A First Tetraplex Assay for the Simultaneous Quantification of Total $\alpha$ -Synuclein, Tau, $\beta$ -Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. <i>PLoS ONE</i> , 2016, 11, e0153564.	1.1	6
21	Protective effect of vagotomy suggests source organ for Parkinson disease. <i>Annals of Neurology</i> , 2015, 78, 834-835.	2.8	12
22	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	2.1	71
23	LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. <i>Nature Immunology</i> , 2015, 16, 898-900.	7.0	26
24	Association between $\alpha$ -synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. <i>Brain</i> , 2015, 138, 2659-2671.	3.7	69
25	Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. <i>Movement Disorders</i> , 2014, 29, 991-998.	2.2	107
26	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	2.8	35
27	Respiratory infection of mice with mammalian reoviruses causes systemic infection with age and strain dependent pneumonia and encephalitis. <i>Virology Journal</i> , 2013, 10, 67.	1.4	17
28	Total CSF $\alpha$ -synuclein is lower in de novo Parkinson patients than in healthy subjects. <i>Neuroscience Letters</i> , 2013, 532, 44-48.	1.0	130
29	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. <i>Neurology</i> , 2013, 81, 1226-1234.	1.5	153
30	Unrecognized vitamin D deficiency is common in Parkinson disease. <i>Neurology</i> , 2013, 81, 1531-1537.	1.5	119
31	Parkin-Dependent Degradation of the F-Box Protein Fbw7 Promotes Neuronal Survival in Response to Oxidative Stress by Stabilizing Mcl-1. <i>Molecular and Cellular Biology</i> , 2013, 33, 3627-3643.	1.1	62
32	Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 15918-15923.	3.3	72
33	Novel One-step Immunoassays to Quantify $\alpha$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2012, 287, 33691-33705.	1.6	51
34	Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of $\alpha$ -synuclein and other proteins in cerebrospinal fluid. <i>Methods</i> , 2012, 56, 514-518.	1.9	30
35	Mutant $\beta$ -Galactosidase Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models. <i>Neurodegenerative Diseases</i> , 2012, 10, 195-202.	0.8	26
36	Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease. <i>Current Treatment Options in Neurology</i> , 2012, 14, 230-240.	0.7	21

#	ARTICLE	IF	CITATIONS
37	Î±-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. <i>Journal of Neural Transmission</i> , 2012, 119, 739-746.	1.4	63
38	Translational Research in Neurology and Neuroscience 2011. <i>Archives of Neurology</i> , 2011, 68, 709-16.	4.9	12
39	Î±-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. <i>Lancet Neurology</i> , The, 2011, 10, 230-240.	4.9	573
40	CSF Î±-synuclein, tau, and amyloid Î² in Parkinson's disease " Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 681-683.	4.9	4
41	Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. <i>Journal of Neural Transmission</i> , 2011, 118, 795-808.	1.4	230
42	Association of <i>SNCA</i> with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study. <i>Movement Disorders</i> , 2011, 26, 2283-2286.	2.2	21
43	Acid Î±-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter Î±-synuclein processing. <i>Annals of Neurology</i> , 2011, 69, 940-953.	2.8	276
44	CNS expression of glucocerebrosidase corrects Î±-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12101-12106.	3.3	282
45	CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 590-591.	0.9	7
46	Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials. <i>Biomarkers in Medicine</i> , 2010, 4, 647-650.	0.6	18
47	Quantification of Î±-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. <i>Biomarkers in Medicine</i> , 2010, 4, 683-699.	0.6	113
48	Expansion of the Parkinson disease-associated SNCA- Rep1 allele upregulates human Î±-synuclein in transgenic mouse brain. <i>Human Molecular Genetics</i> , 2009, 18, 3274-3285.	1.4	101
49	Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. <i>Molecular Neurodegeneration</i> , 2009, 4, 12.	4.4	59
50	Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. <i>Molecular Brain</i> , 2009, 2, 5.	1.3	232
51	Multiple system atrophy: A primary oligodendrogliaopathy. <i>Annals of Neurology</i> , 2008, 64, 239-246.	2.8	279
52	Direct quantification of CSF Î±-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. <i>Experimental Neurology</i> , 2008, 213, 315-325.	2.0	334
53	GATA transcription factors directly regulate the Parkinson's disease-linked gene Î±-synuclein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10907-10912.	3.3	251
54	Purification and Quantification of Neural Î±-synuclein. , 2008, , 559-573.		1

#	ARTICLE	IF	CITATIONS
55	Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 955-960.	3.3	462
56	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. Neurodegenerative Diseases, 2007, 4, 366-375.	0.8	65
57	Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology, 2007, 69, 2093-2104.	1.5	191
58	Chapter 8 $\alpha$ -Synuclein and Synucleinopathies. Blue Books of Neurology, 2007, 30, 186-215.	0.1	4
59	Aggregated $\alpha$ -Synuclein Mediates Dopaminergic Neurotoxicity In Vivo. Journal of Neuroscience, 2007, 27, 3338-3346.	1.7	271
60	Structure of acid $\alpha$ -glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology, 2007, 3, 101-107.	3.9	213
61	The effects of oxidative stress on parkin and other E3 ligases. Journal of Neurochemistry, 2007, 103, 2354-2368.	2.1	78
62	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurology, The, 2007, 6, 652-662.	4.9	290
63	Detection of oligomeric forms of $\alpha$ -synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB Journal, 2006, 20, 419-425.	0.2	646
64	Decreased $\alpha$ -synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications, 2006, 349, 162-166.	1.0	386
65	The genetics of Parkinson disease: implications for neurological care. Nature Clinical Practice Neurology, 2006, 2, 136-146.	2.7	153
66	Parkin Protects against Mitochondrial Toxins and $\alpha$ -Amyloid Accumulation in Skeletal Muscle Cells. Journal of Biological Chemistry, 2006, 281, 12809-12816.	1.6	81
67	Phosphorylation of Ser-129 Is the Dominant Pathological Modification of $\alpha$ -Synuclein in Familial and Sporadic Lewy Body Disease. Journal of Biological Chemistry, 2006, 281, 29739-29752.	1.6	1,113
68	Parkinson's Disease: Assays for the Ubiquitin Ligase Activity of Neural Parkin. , 2005, 301, 351-370.		15
69	Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine, 2005, 11, 1214-1221.	15.2	658
70	Lewy body Parkinson's disease in a large pedigree with 77Parkin mutation carriers. Annals of Neurology, 2005, 58, 411-422.	2.8	252
71	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggregates in response to proteasomal inhibition. Neurobiology of Disease, 2005, 20, 401-411.	2.1	40
72	The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine, 2005, 352, 728-31; author reply 728-31.	13.9	13

#	ARTICLE	IF	CITATIONS
73	Case 27-2004. New England Journal of Medicine, 2004, 351, 912-922.	13.9	13
74	Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Molecular and Cellular Neurosciences, 2004, 27, 236-246.	1.0	58
75	RING finger 1 mutations in Parkin produce altered localization of the protein. Human Molecular Genetics, 2003, 12, 2957-2965.	1.4	138
76	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	1.9	299
77	Colocalization of Parkin with $\hat{1}\pm$ -Synuclein in the Lewy Bodies of Parkinson Disease. Advances in Behavioral Biology, 2002, , 297-300.	0.2	1
78	Ubiquitination of a New Form of alpha -Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease. Science, 2001, 293, 263-269.	6.0	1,033
79	Normal Cellular Processing of the $\hat{1}^2$ -Amyloid Precursor Protein Results in the Secretion of the Amyloid $\hat{1}^2$ Peptide and Related Molecules. Annals of the New York Academy of Sciences, 1993, 695, 109-116.	1.8	112
80	Detection of distinct isoform patterns of the $\hat{1}^2$ -amyloid precursor protein in human platelets and lymphocytes. Neurobiology of Aging, 1992, 13, 421-434.	1.5	61
81	Amyloid $\hat{1}^2$ -peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359, 322-325.	13.7	1,919
82	Detection of soluble forms of the $\hat{1}^2$ -amyloid precursor protein in human plasma. Biochemical and Biophysical Research Communications, 1990, 167, 1094-1101.	1.0	71